Joseph V. Dunn is the Chief Executive Officer of Endogenx. Mr. Dunn has nearly 30 years of senior executive management experience, both in private and publicly traded companies. Mr. Dunn has been the founder, co-founder of several public and privately held organizations, and has served as Chairman, CEO and President, has directed successful restructuring and market turnaround of bio-pharmacology and technology firms with experience in evaluating cutting-edge medical applications, accessing their market potential, strategic partnerships, corporate alliances, and shareholder value.

Anil Gulati, MD, PhD is the Chief Scientific Officer of Endogenx. Dr. Gulati is Professor of Pharmaceutical Sciences and Associate Dean for Research at Midwestern University. He is also a Fulbright Scholar, a program operated by the U.S. Department of State and organized by the Council for International Exchange of Scholars (CIES). Dr. Gulati has developed numerous scientific patents and inventions, and founded two companies which are targeted to be acquired by Endogenx. Dr. Gulati has executed licensing and partnership agreements for his technologies with pharmaceutical companies worldwide. As a physician, pharmacologist, academic professor, biotechnology inventor, and widely-published researcher, Dr. Gulati brings his broad medical research and scientific experience to develop a unique approach for creating specialty pharmaceuticals, therapeutics, and diagnostic products.